Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia

Metabolism: Clinical and Experimental
Jean-Charles HoguePatrick Couture

Abstract

The specific impact of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors and fibrates on the in vivo metabolism of apolipoprotein (apo) B has not been systematically investigated in patients with type 2 diabetes mellitus with high plasma triglyceride (TG) levels. Therefore, the objective of this 2-group parallel study was to examine the differential effects of a 6-week treatment with atorvastatin or fenofibrate on in vivo kinetics of apo B-48 and B-100 in men with type 2 diabetes mellitus with marked hypertriglyceridemia. Apolipoprotein B kinetics were assessed at baseline and at the end of the intervention using a primed constant infusion of [5,5,5-D(3)]-l-leucine for 12 hours in the fed state. Fenofibrate significantly decreased plasma TG levels with no significant change in plasma low-density lipoprotein cholesterol (LDL-C) and apo B levels. On the other hand, atorvastatin significantly reduced plasma levels of TG, LDL-C, and apo B. After treatment with fenofibrate, very low-density lipoprotein (VLDL) apo B-100 pool size (PS) was decreased because of an increase in the fractional catabolic rate (FCR) of VLDL apo B-100. No significant change was observed in the kinetics of LDL apo B-100. Moreover, fenofibrate signifi...Continue Reading

References

Dec 1, 1984·The Journal of Clinical Investigation·J ShepherdH G Morgan
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D W BilheimerJ L Goldstein
Jun 1, 1997·Current Opinion in Lipidology·M W Huff, J R Burnett
Nov 14, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·M CuchelA H Lichtenstein
Jan 23, 1998·Arteriosclerosis, Thrombosis, and Vascular Biology·C J Packard, J Shepherd
Nov 10, 1998·Circulation·B StaelsJ C Fruchart
Dec 11, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·F K WeltyE J Schaefer
Jun 8, 2001·The Journal of Clinical Investigation·G MartinB Staels
Sep 28, 2002·Current Opinion in Lipidology·Spencer D ProctorJohn C L Mamo
Apr 3, 2003·Journal of Lipid Research·Klaus G ParhoferP Hugh R Barrett
Apr 10, 2003·The Journal of Pharmacology and Experimental Therapeutics·Khadija OuguerramMichel Krempf
Jun 5, 2003·Journal of Lipid Research·Isabelle L RuelBenoît Lamarche
Jun 25, 2003·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·G F WattsG R Thompson
Feb 27, 2004·Diabetes, Obesity & Metabolism·Andrew J Krentz
Feb 25, 2005·Current Atherosclerosis Reports·ThB TwicklerJ S Cohn
Jan 13, 2006·Current Opinion in Lipidology·Dick C ChanGerald F Watts
Mar 11, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·André J TremblayPatrick Couture
Apr 15, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Hélène DuezGary F Lewis

❮ Previous
Next ❯

Citations

Jan 25, 2013·Current Atherosclerosis Reports·D C ChanG F Watts
Oct 16, 2009·Current Opinion in Lipidology·Catherine Fiévet, Bart Staels
Apr 11, 2013·Current Opinion in Lipidology·Stefania Lamon-Fava
Apr 5, 2012·Journal of Lipid Research·Margaret R DiffenderferErnst J Schaefer
Mar 25, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Cesare R Sirtori
Dec 7, 2011·Expert Review of Clinical Pharmacology·Jeffrey S Freeman, Benjamin Gross
Mar 31, 2012·Expert Review of Cardiovascular Therapy·Adie Viljoen, Anthony S Wierzbicki
Nov 21, 2008·Expert Review of Cardiovascular Therapy·Robert S Rosenson
Mar 29, 2014·Current Medical Research and Opinion·Angela PirilloAlberico Luigi Catapano
Sep 4, 2012·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Juan Patricio Nogueira, Fernando Daniel Brites
Oct 18, 2011·Biochimica Et Biophysica Acta·Changting Xiao, Gary F Lewis
Nov 10, 2015·Clinical Therapeutics·Damon A Bell, Gerald F Watts
Apr 27, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Shu-Meng ChengJenn-Haung Lai
Aug 5, 2008·Atherosclerosis. Supplements·Hélène DuezGary F Lewis
May 15, 2015·Annual Review of Nutrition·Satya DashGary F Lewis
Aug 2, 2014·Progress in Lipid Research·Amirhossein SahebkarGerald F Watts
Dec 17, 2009·Atherosclerosis·Ashish ShahJohn S Millar
Mar 13, 2012·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Stephen J Nicholls, Kiyoko Uno
Aug 10, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·Heiner K BertholdIoanna Gouni-Berthold
Mar 12, 2015·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Apr 28, 2010·Nature Reviews. Endocrinology·Allan SnidermanJacqueline de Graaf
May 31, 2018·Expert Review of Clinical Pharmacology·Rabia ChaudhryAnthony S Wierzbicki
May 18, 2018·Journal of Lipid Research·Allan D SnidermanGeorge Thanassoulis
Jun 28, 2018·Journal of Lipid Research·Jean-Philippe Drouin-ChartierPatrick Couture
Jun 21, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Martin AdielsJan Borén
Jun 23, 2011·American Journal of Physiology. Endocrinology and Metabolism·Changting XiaoGary F Lewis
Apr 16, 2020·Diabetology & Metabolic Syndrome·Catherine LalandeAlain Veilleux
May 18, 2021·Frontiers in Cardiovascular Medicine·Yixi ZhaoMin Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.